Welcome to our dedicated page for QuidelOrtho SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QuidelOrtho's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QuidelOrtho's regulatory disclosures and financial reporting.
QuidelOrtho Corporation announced a planned leadership transition in its top legal role. Chief Legal Officer and Corporate Secretary Michelle A. Hodges will retire from these positions effective March 23, 2026, with a transition and retirement agreement supporting an orderly handover of her duties.
For up to six months, Ms. Hodges will continue receiving her current base salary and benefits while transitioning responsibilities. She will then serve as special advisor to the Chief Executive Officer for up to twenty-four months, initially at her current base salary rate, which will be reduced by 50% for the remainder of the advisory term, while remaining eligible for employee benefits, annual bonus and equity grant opportunities, and continued vesting of existing equity awards.
The Board of Directors appointed Nathaniel “Nate” Sisitsky as the new Chief Legal Officer and Corporate Secretary, effective as of the same date. With more than 25 years of legal and governance experience at public life sciences and technology companies, including prior Chief Legal Officer and Corporate Secretary roles, he will lead QuidelOrtho’s global legal, compliance and corporate governance functions.
QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an amended insider transaction reflecting an open-market purchase of 3,370 shares of common stock on February 13, 2026, acquired indirectly through a trust at a weighted average price of $23.6623 per share.
The amendment corrects the pricing details, noting a purchase price range from $23.0150 to $23.6750 per share. Following these transactions, Busky’s indirect holdings held by a trust total 10,290 shares, and his direct ownership stands at 41,412 shares of QuidelOrtho common stock.
QuidelOrtho Corporation provides a detailed annual overview of its global diagnostics business, spanning Labs, Molecular Diagnostics, Point of Care and Transfusion Medicine across more than 140 countries. The company highlights U.S. manufacturing and service scale, including about 6,500 employees and roughly 1,200 service staff.
QuidelOrtho is winding down its U.S. donor screening portfolio, including the VIP platform and microplate assays, with completion expected by the first half of 2026, and has decided to discontinue development of the SAVANNA molecular platform. Respiratory products represented about 15% of total 2025 revenues, reflecting strong seasonality.
The company continues to invest in R&D, with expenses of $186.2 million, $218.7 million and $245.0 million for fiscal years 2025, 2024 and 2023, respectively. It recorded a $65 million charge payable to Grifols over three years tied to mutually agreed terms in principle for an early termination of their long‑running Joint Business arrangement. As of February 11, 2026, 68,081,767 common shares were outstanding, and the aggregate market value of common stock held by non‑affiliates was $1,940,523,408 as of the last business day of the most recent second fiscal quarter.
QuidelOrtho Corporation reported that its Chief Financial Officer and principal financial officer, Joseph M. Busky, has informed the company of his plans to retire, effective June 30, 2026. The company states that his decision is for personal reasons and not due to any disagreement regarding financial statements, operations, policies, or practices. This advance notice gives QuidelOrtho time to manage the transition in its senior financial leadership.
Strobeck Matthew reported open-market purchase transactions in a Form 4 filing for QDEL. The filing lists transactions totaling 10,000 shares at a weighted average price of $23.96 per share. Following the reported transactions, holdings were 27,775 shares.
QuidelOrtho Corporation received an amended ownership report showing that investment adviser Rubric Capital Management LP and David Rosen together beneficially own 3,777,157 shares of QuidelOrtho common stock, representing 5.56% of the outstanding shares.
The filing states Rubric Capital advises funds that hold these shares, including Rubric Capital Master Fund LP, which has the right to receive dividends or sale proceeds on more than 5% of the stock. The securities are reported as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.
QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an open‑market purchase of common stock. On February 13, 2026, a trust associated with him bought 3,370 shares at $23.6623 per share, bringing its indirect holdings to 10,290 shares and his direct holdings to 41,412 shares.
QuidelOrtho Corp President and CEO Brian J. Blaser reported an indirect open-market purchase of common stock through a trust associated with him. On February 13, 2026, the trust bought 10,540 shares at a weighted average price of $23.5921 per share, within a range of $23.4200 to $23.9400.
After this transaction, the trust held 40,073 shares of QuidelOrtho common stock indirectly for Blaser, while he also held 25,142 shares directly. The filing notes that detailed trade-by-trade pricing is available upon request from the reporting person.
Invesco Ltd. reports beneficial ownership of 3,470,656 shares of QuidelOrtho Corp common stock, representing 5.1% of the class as of 12/31/2025. Invesco has sole voting power over 3,450,932 shares and sole dispositive power over 3,470,656 shares, with no shared powers.
The shares are held of record by clients of Invesco’s investment advisers, including Invesco Advisers, Inc. and Invesco Capital Management LLC. Invesco certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.
QuidelOrtho Corporation reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year 2025 revenue was $2.73 billion, slightly below 2024, as respiratory revenue fell 20% to $402.1 million with lower COVID-19 testing, while non-respiratory revenue reached $2.33 billion.
The company posted a 2025 GAAP net loss of $1.13 billion and a GAAP operating loss of $0.92 billion, driven largely by a $701 million non-cash goodwill impairment charge. Despite this, adjusted EBITDA was $597 million with a 22% adjusted EBITDA margin, a 240 basis point improvement.
Free cash flow was $(77) million in 2025, reflecting one-time ERP system investments, but management expects free cash flow to improve by over $200 million in 2026, guiding to $120–$160 million. 2026 guidance calls for $2.7–$2.9 billion in revenue, adjusted EBITDA of $630–$670 million, and adjusted EPS of $2.00–$2.42. The company also announced that Chief Financial Officer Joseph M. Busky plans to retire effective June 30, 2026.